South Korean drugmaker Daewoong Pharmaceutical Co Ltd said on Monday that it had received regulatory approval for Phase 1 clinical trials of its anti-parasitic niclosamide drug to treat COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback